Degron: VNTSS
90.06
0.955
0.3738
0.653
0.0292
0.9771
0.6235
Degron related mutations and impact score
| Mutation | Sample | Cancer | Dataset | Degron | Degron class | Impact score |
| p.S1055T | TCGA-AD-6889 | COAD | TCGA | VNTSS | DEG_SPOP_SBC_1 | 0.6005 |
| p.S1055T | DO8463 | COAD | ICGC | VNTSS | DEG_SPOP_SBC_1 | 0.6005 |
| p.A1045D | TCGA-CN-6021 | HNSC | TCGA | VNTSS | DEG_SPOP_SBC_1 | 0.1389 |
| p.A1045D | DO15847 | HNSC | ICGC | VNTSS | DEG_SPOP_SBC_1 | 0.1389 |
| p.P1042S | TCGA-EE-A182 | SKCM | TCGA | VNTSS | DEG_SPOP_SBC_1 | 0.0556 |
| p.P1042S | TCGA-ER-A19M | SKCM | TCGA | VNTSS | DEG_SPOP_SBC_1 | 0.0556 |
| p.P1042S | DO37814 | SKCM | ICGC | VNTSS | DEG_SPOP_SBC_1 | 0.0556 |
| p.P1042S | DO37798 | SKCM | ICGC | VNTSS | DEG_SPOP_SBC_1 | 0.0556 |
| p.P1042L | TCGA-ER-A19M | SKCM | TCGA | VNTSS | DEG_SPOP_SBC_1 | 0.0556 |
| p.P1042L | DO37798 | SKCM | ICGC | VNTSS | DEG_SPOP_SBC_1 | 0.0556 |
| p.S1043R | DO229006 | LICA | ICGC | VNTSS | DEG_SPOP_SBC_1 | 0.0833 |
| p.T1057N | DO228887 | LICA | ICGC | VNTSS | DEG_SPOP_SBC_1 | 0.3056 |
| p.T1057P | SIDM00529 | Breast Carcinoma | GDSC | VNTSS | DEG_SPOP_SBC_1 | 0.3056 |
| p.T1057P | ACH-000621 | Breast Cancer | CCLE | VNTSS | DEG_SPOP_SBC_1 | 0.3056 |
| p.T1057P | MDA-MB-157 | breast | COSMIC | VNTSS | DEG_SPOP_SBC_1 | 0.3056 |
| p.E1051Q | SIDM00133 | Non-Small Cell Lung Carcinoma | GDSC | VNTSS | DEG_SPOP_SBC_1 | 0.3056 |
| p.E1051Q | ACH-000861 | Lung Cancer | CCLE | VNTSS | DEG_SPOP_SBC_1 | 0.3056 |
| p.E1051Q | HOP-62 | lung | COSMIC | VNTSS | DEG_SPOP_SBC_1 | 0.3056 |
Drug responses associated with PDGFRB mutations
| Sample | Cancer | Mutation (In Degron?) | Dataset | Drug | IC50 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Sunitinib | 1.6747 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Sorafenib | 1.5857 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Imatinib | 11.1118 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Dasatinib | 0.829 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Pazopanib | 13.2603 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Masitinib | 15.6107 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Foretinib | 0.6622 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 12.799 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | BIBF-1120 | 1.883 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Axitinib | 3.0726 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Motesanib | 10.1631 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Dasatinib | 3.3618 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Sorafenib | 2.4782 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Cediranib | 5.7895 |
| SIDM00495 | DLBC|B_cell_lymphoma | p.I29F (No) | GDSC | Foretinib | 0.7761 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Pazopanib | 134.2914 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Masitinib | 170.627 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Foretinib | 4.4547 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 122.1622 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | BIBF-1120 | 59.9625 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Axitinib | 5.575 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Motesanib | 27.7313 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Dasatinib | 0.9012 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Sorafenib | 161.64 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Cediranib | 13.972 |
| SIDM00720 | MESO|mesothelioma | p.I29F (No) | GDSC | Foretinib | 4.3087 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Sunitinib | 1.7779 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Sorafenib | 8.663 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Imatinib | 8.7275 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Dasatinib | 0.0013 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Pazopanib | 5.9245 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Masitinib | 2.8406 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Foretinib | 0.3032 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Brivanib, BMS-540215 | 40.962 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | BIBF-1120 | 0.0485 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Axitinib | 3.5113 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Motesanib | 4.4666 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Dasatinib | 0.0007 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Sorafenib | 5.3571 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Cediranib | 0.9535 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.M772I (No) | GDSC | Foretinib | 0.6026 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Sunitinib | 1.7779 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Sorafenib | 8.663 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Imatinib | 8.7275 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Dasatinib | 0.0013 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Pazopanib | 5.9245 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Masitinib | 2.8406 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Foretinib | 0.3032 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Brivanib, BMS-540215 | 40.962 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | BIBF-1120 | 0.0485 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Axitinib | 3.5113 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Motesanib | 4.4666 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Dasatinib | 0.0007 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Sorafenib | 5.3571 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Cediranib | 0.9535 |
| SIDM00951 | LAML|acute_myeloid_leukaemia | p.N244D (No) | GDSC | Foretinib | 0.6026 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Pazopanib | 200.4516 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Masitinib | 130.9385 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Foretinib | 7.298 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Brivanib, BMS-540215 | 146.1156 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | BIBF-1120 | 36.3656 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Axitinib | 34.4935 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Motesanib | 28.4604 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Dasatinib | 91.676 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Sorafenib | 29.618 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Cediranib | 13.981 |
| SIDM00680 | COREAD|large_intestine | p.T369M (No) | GDSC | Foretinib | 6.5598 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Pazopanib | 50.5275 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Masitinib | 77.1652 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Foretinib | 1.2098 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Brivanib, BMS-540215 | 95.9907 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | BIBF-1120 | 11.7001 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Axitinib | 4.9899 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Motesanib | 22.6324 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Dasatinib | 52.013 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Sorafenib | 26.245 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Cediranib | 7.2177 |
| SIDM00499 | PRAD|prostate | p.R853W (No) | GDSC | Foretinib | 10.161 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Sunitinib | 8.2586 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Sorafenib | 4.0283 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Imatinib | 0.1788 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Dasatinib | 0.0017 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Pazopanib | 29.2919 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Masitinib | 0.367 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Foretinib | 0.35 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Brivanib, BMS-540215 | 14.9237 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | BIBF-1120 | 0.752 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Axitinib | 0.5271 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Motesanib | 13.7197 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Dasatinib | 0.001 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Sorafenib | 6.545 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Cediranib | 6.3101 |
| SIDM01004 | LCML|chronic_myeloid_leukaemia | p.R456S (No) | GDSC | Foretinib | 0.5519 |
| SIDM00966 | OV|ovary | p.S55L (No) | GDSC | Masitinib | 80.2983 |
| SIDM00966 | OV|ovary | p.S55L (No) | GDSC | Foretinib | 0.9911 |
| SIDM00966 | OV|ovary | p.S55L (No) | GDSC | Brivanib, BMS-540215 | 88.6978 |
| SIDM00966 | OV|ovary | p.S55L (No) | GDSC | BIBF-1120 | 139.2044 |
| SIDM00966 | OV|ovary | p.S55L (No) | GDSC | Axitinib | 3.2713 |
| SIDM00966 | OV|ovary | p.S55L (No) | GDSC | Motesanib | 25.9621 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Pazopanib | 160.3341 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Masitinib | 47.8647 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Foretinib | 0.3556 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Brivanib, BMS-540215 | 394.7671 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | BIBF-1120 | 15.639 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Axitinib | 28.5074 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Motesanib | 4.9194 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Dasatinib | 0.6744 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Sorafenib | 40.342 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Cediranib | 6.2132 |
| SIDM01139 | PAAD|pancreas | p.V316M (No) | GDSC | Foretinib | 1.0997 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Sunitinib | 7.6995 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Sorafenib | 5.6456 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Imatinib | 27.0124 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Dasatinib | 4.7849 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Pazopanib | 25.5864 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Masitinib | 37.2289 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Foretinib | 1.7957 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Brivanib, BMS-540215 | 360.8232 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | BIBF-1120 | 23.6128 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Axitinib | 31.6666 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Motesanib | 17.3508 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Dasatinib | 24.321 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Sorafenib | 19.257 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Cediranib | 12.764 |
| SIDM00108 | SKCM|melanoma | p.A1096V (No) | GDSC | Foretinib | 4.0544 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Sunitinib | 0.0435 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Sorafenib | 0.3729 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Imatinib | 1.3028 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Dasatinib | 0.0124 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Pazopanib | 0.8107 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Masitinib | 6.222 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Foretinib | 0.1192 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 12.5674 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | BIBF-1120 | 0.3349 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Axitinib | 2.2577 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Motesanib | 9.3374 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Dasatinib | 0.2601 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Sorafenib | 6.8327 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Cediranib | 1.735 |
| SIDM00242 | UNCLASSIFIED|osteosarcoma | p.I29F (No) | GDSC | Foretinib | 0.4947 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Pazopanib | 51.2626 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Masitinib | 24.7842 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Foretinib | 2.1823 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Brivanib, BMS-540215 | 258.7973 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | BIBF-1120 | 248.8056 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Axitinib | 18.6244 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Motesanib | 15.1613 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Dasatinib | 2.7759 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Sorafenib | 84.408 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Cediranib | 59.312 |
| SIDM00353 | UNCLASSIFIED|ovary | p.R685C (No) | GDSC | Foretinib | 48.067 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Sunitinib | 6.3543 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Sorafenib | 1.6928 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Imatinib | 19.7629 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Dasatinib | 3.9124 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Pazopanib | 0.8446 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Masitinib | 3.8864 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Foretinib | 0.2346 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 2.9419 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | BIBF-1120 | 1.4633 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Axitinib | 0.3936 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Motesanib | 17.0421 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Dasatinib | 2.5759 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Sorafenib | 2.904 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Cediranib | 5.0396 |
| SIDM00785 | LAML|acute_myeloid_leukaemia | p.I29F (No) | GDSC | Foretinib | 0.8103 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Pazopanib | 10.54 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Masitinib | 24.8308 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Foretinib | 1.6887 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Brivanib, BMS-540215 | 37.7911 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | BIBF-1120 | 11.9516 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Axitinib | 8.4717 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Motesanib | 13.9083 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Dasatinib | 26.343 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Sorafenib | 9.1906 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Cediranib | 10.023 |
| SIDM00828 | UNCLASSIFIED|fibrosarcoma | p.R502Q (No) | GDSC | Foretinib | 21.726 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Pazopanib | 13.3584 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Masitinib | 71.0858 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Foretinib | 0.8891 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 139.4063 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | BIBF-1120 | 183.8759 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Axitinib | 1.5925 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Motesanib | 6.3467 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Dasatinib | 6.1214 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Sorafenib | 8.8385 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Cediranib | 24.239 |
| SIDM00846 | CESC|cervix | p.I29F (No) | GDSC | Foretinib | 1.4891 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Sunitinib | 2.0565 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Sorafenib | 4.9994 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Imatinib | 8.9862 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Dasatinib | 0.899 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Pazopanib | 9.0608 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Masitinib | 8.8751 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Foretinib | 0.1908 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Brivanib, BMS-540215 | 38.3399 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | BIBF-1120 | 1.9963 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Axitinib | 2.2297 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Motesanib | 12.841 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Dasatinib | 0.7811 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Sorafenib | 3.5437 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Cediranib | 3.4309 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.A713T (No) | GDSC | Foretinib | 0.4275 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Sunitinib | 2.0565 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Sorafenib | 4.9994 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Imatinib | 8.9862 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Dasatinib | 0.899 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Pazopanib | 9.0608 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Masitinib | 8.8751 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Foretinib | 0.1908 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Brivanib, BMS-540215 | 38.3399 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | BIBF-1120 | 1.9963 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Axitinib | 2.2297 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Motesanib | 12.841 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Dasatinib | 0.7811 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Sorafenib | 3.5437 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Cediranib | 3.4309 |
| SIDM01007 | ALL|lymphoblastic_leukemia | p.H277Q (No) | GDSC | Foretinib | 0.4275 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Sunitinib | 64.3744 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Imatinib | 44.3661 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Dasatinib | 0.8233 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Pazopanib | 34.8312 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Masitinib | 92.2475 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Foretinib | 3.9915 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Brivanib, BMS-540215 | 215.6557 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | BIBF-1120 | 20.4673 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Axitinib | 21.2293 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Motesanib | 41.424 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Dasatinib | 8.6608 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Sorafenib | 56.327 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Cediranib | 14.851 |
| SIDM00781 | COREAD|large_intestine | p.P427S (No) | GDSC | Foretinib | 10.275 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Sunitinib | 64.3744 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Imatinib | 44.3661 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Dasatinib | 0.8233 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Pazopanib | 34.8312 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Masitinib | 92.2475 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Foretinib | 3.9915 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 215.6557 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | BIBF-1120 | 20.4673 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Axitinib | 21.2293 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Motesanib | 41.424 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Dasatinib | 8.6608 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Sorafenib | 56.327 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Cediranib | 14.851 |
| SIDM00781 | COREAD|large_intestine | p.I29F (No) | GDSC | Foretinib | 10.275 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Sunitinib | 201.0901 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Sorafenib | 67.5275 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Imatinib | 50.8589 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Dasatinib | 12.7437 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Pazopanib | 244.3498 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Masitinib | 649.402 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Foretinib | 24.0044 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Brivanib, BMS-540215 | 495.8458 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | BIBF-1120 | 163.7589 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Axitinib | 15.5588 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Motesanib | 67.1185 |
| SIDM00719 | SCLC|lung_small_cell_carcinoma | p.R502W (No) | GDSC | Foretinib | 7.2808 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Pazopanib | 140.369 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Masitinib | 333.3923 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Foretinib | 137.1299 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 537.3217 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | BIBF-1120 | 486.198 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Axitinib | 20.9335 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Motesanib | 68.2827 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Dasatinib | 0.7739 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Sorafenib | 30.334 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Cediranib | 5.4432 |
| SIDM00381 | CESC|cervix | p.I29F (No) | GDSC | Foretinib | 3.1864 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Pazopanib | 354.983 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Masitinib | 483.409 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Foretinib | 5.5521 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Brivanib, BMS-540215 | 43.5227 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | BIBF-1120 | 56.6172 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Axitinib | 17.9822 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Motesanib | 51.2986 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Dasatinib | 265.38 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Sorafenib | 47.379 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Cediranib | 47.112 |
| SIDM00755 | LUAD|lung_NSCLC_adenocarcinoma | p.T369R (No) | GDSC | Foretinib | 27.967 |
| SIDM00393 | STAD|stomach | p.A1096V (No) | GDSC | Axitinib | 4.2697 |
| SIDM00393 | STAD|stomach | p.A1096V (No) | GDSC | Motesanib | 10.2222 |
| SIDM00393 | STAD|stomach | p.A1096V (No) | GDSC | Dasatinib | 0.5865 |
| SIDM00393 | STAD|stomach | p.A1096V (No) | GDSC | Sorafenib | 12.023 |
| SIDM00393 | STAD|stomach | p.A1096V (No) | GDSC | Cediranib | 7.4178 |
| SIDM00393 | STAD|stomach | p.A1096V (No) | GDSC | Foretinib | 0.7473 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Pazopanib | 16.5006 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Masitinib | 123.565 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Foretinib | 1.1196 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Brivanib, BMS-540215 | 536.7401 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | BIBF-1120 | 46.9747 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Axitinib | 55.356 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Motesanib | 42.0156 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Dasatinib | 0.2994 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Sorafenib | 465.72 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Cediranib | 26.799 |
| SIDM00943 | PAAD|pancreas | p.R502Q (No) | GDSC | Foretinib | 3.7833 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Sunitinib | 4.4854 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Imatinib | 13.8763 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Dasatinib | 0.1909 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Pazopanib | 6.5257 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Masitinib | 120.8767 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Foretinib | 18.4258 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Brivanib, BMS-540215 | 40.8773 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | BIBF-1120 | 9.6454 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Axitinib | 12.7993 |
| SIDM00052 | ESCA|oesophagus | p.V480M (No) | GDSC | Motesanib | 17.5966 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Sunitinib | 4.4854 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Imatinib | 13.8763 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Dasatinib | 0.1909 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Pazopanib | 6.5257 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Masitinib | 120.8767 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Foretinib | 18.4258 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 40.8773 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | BIBF-1120 | 9.6454 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Axitinib | 12.7993 |
| SIDM00052 | ESCA|oesophagus | p.I29F (No) | GDSC | Motesanib | 17.5966 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Pazopanib | 101.3814 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Masitinib | 41.2876 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Foretinib | 1.4005 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Brivanib, BMS-540215 | 256.8155 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | BIBF-1120 | 131.0512 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Axitinib | 5.1237 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Motesanib | 14.5591 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Dasatinib | 0.4009 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Sorafenib | 27.694 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Cediranib | 4.81 |
| SIDM00936 | BLCA|bladder | p.R502Q (No) | GDSC | Foretinib | 6.6342 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Sunitinib | 32.9884 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Sorafenib | 23.1136 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Imatinib | 22.4405 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Dasatinib | 3.0093 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Pazopanib | 39.9761 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Masitinib | 16.9741 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Foretinib | 1.7568 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Brivanib, BMS-540215 | 32.604 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | BIBF-1120 | 17.8348 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Axitinib | 5.6759 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Motesanib | 21.6377 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Dasatinib | 22.696 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Sorafenib | 8.6471 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Cediranib | 48.075 |
| SIDM01058 | DLBC|B_cell_lymphoma | p.V316M (No) | GDSC | Foretinib | 10.54 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sunitinib | 24.1348 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sorafenib | 13.0112 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Imatinib | 22.7497 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Dasatinib | 4.024 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Pazopanib | 80.8409 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Masitinib | 19.637 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Foretinib | 3.0346 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 16.6215 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | BIBF-1120 | 13.3488 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Axitinib | 20.2843 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Motesanib | 19.9159 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Dasatinib | 6.0126 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sorafenib | 4.4401 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Cediranib | 5.0925 |
| SIDM00844 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Foretinib | 6.6381 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Sunitinib | 2.8272 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Sorafenib | 6.9852 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Imatinib | 22.3141 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Dasatinib | 4.6352 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Pazopanib | 23.848 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Masitinib | 17.2084 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Foretinib | 3.0561 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Brivanib, BMS-540215 | 52.7285 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | BIBF-1120 | 38.929 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Axitinib | 9.7418 |
| SIDM01039 | UNCLASSIFIED|urogenital_system_other | p.T464M (No) | GDSC | Motesanib | 18.8844 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Sunitinib | 3.1015 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Sorafenib | 3.8856 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Imatinib | 11.4273 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Dasatinib | 1.2752 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Pazopanib | 27.0241 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Masitinib | 2.1638 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Foretinib | 0.968 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Brivanib, BMS-540215 | 33.3727 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | BIBF-1120 | 11.8519 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Axitinib | 8.228 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Motesanib | 15.3786 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Dasatinib | 4.7931 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Sorafenib | 4.7188 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Cediranib | 5.5524 |
| SIDM00946 | ALL|T_cell_leukemia | p.Y904fs*32 (No) | GDSC | Foretinib | 3.7541 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Pazopanib | 24.3245 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Masitinib | 62.6954 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Foretinib | 2.3885 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Brivanib, BMS-540215 | 54.1114 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | BIBF-1120 | 4.0896 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Axitinib | 11.5011 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Motesanib | 6.2433 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Axitinib | 20.257 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Dasatinib | 27.395 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Sorafenib | 13.89 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Cediranib | 24.919 |
| SIDM00529 | BRCA|breast | p.T1057P (Yes) | GDSC | Foretinib | 3.4666 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Pazopanib | 24.3245 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Masitinib | 62.6954 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 2.3885 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 54.1114 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | BIBF-1120 | 4.0896 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 11.5011 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Motesanib | 6.2433 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 20.257 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Dasatinib | 27.395 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Sorafenib | 13.89 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Cediranib | 24.919 |
| SIDM00529 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 3.4666 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.T88I (No) | GDSC | Axitinib | 1.527 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.T88I (No) | GDSC | Motesanib | 11.0607 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.T88I (No) | GDSC | Dasatinib | 4.5575 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.T88I (No) | GDSC | Sorafenib | 3.4072 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.T88I (No) | GDSC | Cediranib | 5.862 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.T88I (No) | GDSC | Foretinib | 0.2787 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.I29F (No) | GDSC | Axitinib | 1.527 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.I29F (No) | GDSC | Motesanib | 11.0607 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.I29F (No) | GDSC | Dasatinib | 4.5575 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.I29F (No) | GDSC | Sorafenib | 3.4072 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.I29F (No) | GDSC | Cediranib | 5.862 |
| SIDM00431 | ALL|lymphoblastic_T_cell_leukaemia | p.I29F (No) | GDSC | Foretinib | 0.2787 |
| SIDM01117 | SCLC|lung_small_cell_carcinoma | p.M937V (No) | GDSC | Sunitinib | 132.4436 |
| SIDM01117 | SCLC|lung_small_cell_carcinoma | p.M937V (No) | GDSC | Sorafenib | 19.5654 |
| SIDM01117 | SCLC|lung_small_cell_carcinoma | p.M937V (No) | GDSC | Imatinib | 43.1973 |
| SIDM01117 | SCLC|lung_small_cell_carcinoma | p.M937V (No) | GDSC | Dasatinib | 15.7151 |
| SIDM01117 | SCLC|lung_small_cell_carcinoma | p.M937V (No) | GDSC | Pazopanib | 112.5232 |
| SIDM01117 | SCLC|lung_small_cell_carcinoma | p.M937V (No) | GDSC | Masitinib | 147.5028 |
| SIDM01117 | SCLC|lung_small_cell_carcinoma | p.M937V (No) | GDSC | Foretinib | 4.2864 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Sunitinib | 5.8574 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Sorafenib | 3.2571 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Imatinib | 14.9796 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Dasatinib | 0.3019 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Pazopanib | 11.1404 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Masitinib | 17.5401 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Foretinib | 0.3712 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Brivanib, BMS-540215 | 63.0613 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | BIBF-1120 | 22.0568 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Axitinib | 5.4185 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Motesanib | 21.9259 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Dasatinib | 8.5368 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Sorafenib | 5.6057 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Cediranib | 6.792 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.M754T (No) | GDSC | Foretinib | 4.5486 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Sunitinib | 5.8574 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Sorafenib | 3.2571 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Imatinib | 14.9796 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Dasatinib | 0.3019 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Pazopanib | 11.1404 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Masitinib | 17.5401 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Foretinib | 0.3712 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Brivanib, BMS-540215 | 63.0613 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | BIBF-1120 | 22.0568 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Axitinib | 5.4185 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Motesanib | 21.9259 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Dasatinib | 8.5368 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Sorafenib | 5.6057 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Cediranib | 6.792 |
| SIDM00388 | UNCLASSIFIED|B_cell_leukemia | p.P462S (No) | GDSC | Foretinib | 4.5486 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sunitinib | 8.9213 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sorafenib | 9.5131 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Imatinib | 29.9004 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Dasatinib | 0.6739 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Pazopanib | 31.1062 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Masitinib | 16.6885 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Foretinib | 1.2719 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 32.1431 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | BIBF-1120 | 5.4608 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Axitinib | 34.3358 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Motesanib | 24.8288 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Dasatinib | 2.4148 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sorafenib | 6.2141 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Cediranib | 5.0361 |
| SIDM00793 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Foretinib | 5.5147 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Sunitinib | 3.1015 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Sorafenib | 3.8856 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Imatinib | 11.4273 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Dasatinib | 1.2752 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Pazopanib | 27.0241 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Masitinib | 2.1638 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Foretinib | 0.968 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Brivanib, BMS-540215 | 33.3727 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | BIBF-1120 | 11.8519 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Axitinib | 8.228 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Motesanib | 15.3786 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Dasatinib | 4.7931 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Sorafenib | 4.7188 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Cediranib | 5.5524 |
| SIDM00946 | ALL|T_cell_leukemia | p.T248A (No) | GDSC | Foretinib | 3.7541 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Pazopanib | 17.8762 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Masitinib | 58.6559 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Foretinib | 7.9117 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Brivanib, BMS-540215 | 49.6068 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | BIBF-1120 | 9.7502 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Axitinib | 16.5624 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Dasatinib | 0.6764 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Sorafenib | 10.585 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Cediranib | 8.9193 |
| SIDM00853 | UNCLASSIFIED|soft_tissue_other | p.R437C (No) | GDSC | Foretinib | 2.6561 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Pazopanib | 9.3119 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Masitinib | 24.6758 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Foretinib | 2.8306 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Brivanib, BMS-540215 | 68.9695 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | BIBF-1120 | 15.4151 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Axitinib | 17.1661 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Motesanib | 2.8772 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Dasatinib | 12.799 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Sorafenib | 8.8517 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Cediranib | 5.4692 |
| SIDM00333 | UCEC|endometrium | p.Q155* (No) | GDSC | Foretinib | 7.9407 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Pazopanib | 70.3908 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Masitinib | 23.6792 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Foretinib | 1.1127 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 95.0412 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | BIBF-1120 | 32.6291 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Axitinib | 3.9649 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Motesanib | 8.7254 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Dasatinib | 1.3473 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Sorafenib | 12.108 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Cediranib | 2.9341 |
| SIDM00598 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.I29F (No) | GDSC | Foretinib | 1.4059 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Pazopanib | 44.9794 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Masitinib | 113.5843 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Foretinib | 1.187 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Brivanib, BMS-540215 | 17.4625 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | BIBF-1120 | 10.8939 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Axitinib | 2.4148 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Motesanib | 4.9658 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Dasatinib | 7.8487 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Sorafenib | 8.0689 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Cediranib | 5.4135 |
| SIDM00999 | BLCA|bladder | p.R177C (No) | GDSC | Foretinib | 1.4814 |
| SIDM00217 | COREAD|large_intestine | p.R397Q (No) | GDSC | Masitinib | 29.5935 |
| SIDM00217 | COREAD|large_intestine | p.R397Q (No) | GDSC | Foretinib | 1.6723 |
| SIDM00217 | COREAD|large_intestine | p.R397Q (No) | GDSC | Brivanib, BMS-540215 | 386.8326 |
| SIDM00217 | COREAD|large_intestine | p.R397Q (No) | GDSC | BIBF-1120 | 16.5032 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Sunitinib | 8.8775 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Sorafenib | 2.3348 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Imatinib | 10.8536 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Dasatinib | 3.1155 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Pazopanib | 24.6815 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Masitinib | 13.3911 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Foretinib | 0.222 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Brivanib, BMS-540215 | 15.7665 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | BIBF-1120 | 4.6435 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Axitinib | 2.2851 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Motesanib | 9.2465 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Dasatinib | 2.2379 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Sorafenib | 6.6214 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Cediranib | 6.1995 |
| SIDM01247 | UNCLASSIFIED|Burkitt_lymphoma | p.T369M (No) | GDSC | Foretinib | 1.1313 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Sunitinib | 81.4875 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Sorafenib | 22.9832 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Imatinib | 21.249 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Dasatinib | 8.5377 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Pazopanib | 99.8015 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Masitinib | 24.1337 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Foretinib | 0.5981 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 35.4266 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | BIBF-1120 | 6.0998 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Axitinib | 20.5891 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Motesanib | 4.7836 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Dasatinib | 43.11 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Sorafenib | 6.7916 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Cediranib | 9.9431 |
| SIDM00492 | GBM|glioma | p.I29F (No) | GDSC | Foretinib | 3.1392 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Pazopanib | 25.3503 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Masitinib | 173.4662 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Foretinib | 4.3302 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Brivanib, BMS-540215 | 85.6761 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | BIBF-1120 | 18.3251 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Axitinib | 4.5103 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Motesanib | 21.1064 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Dasatinib | 24.115 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Sorafenib | 19.559 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Cediranib | 102.86 |
| SIDM00596 | UCEC|endometrium | p.V35I (No) | GDSC | Foretinib | 45.124 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Sunitinib | 189.499 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Sorafenib | 61.3342 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Imatinib | 51.6867 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Dasatinib | 34.4884 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Pazopanib | 234.9693 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Masitinib | 38.2671 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Foretinib | 7.5179 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Brivanib, BMS-540215 | 66.1763 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | BIBF-1120 | 39.5796 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Axitinib | 50.4847 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Motesanib | 57.5889 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Dasatinib | 11.536 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Sorafenib | 7.9982 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Cediranib | 11.404 |
| SIDM00282 | COREAD|large_intestine | p.I679N (No) | GDSC | Foretinib | 8.0375 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Sunitinib | 17.377 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Sorafenib | 37.9394 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Imatinib | 17.615 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Dasatinib | 0.112 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Pazopanib | 89.8976 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Masitinib | 32.7404 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Foretinib | 1.5423 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Brivanib, BMS-540215 | 419.28 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | BIBF-1120 | 198.579 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Axitinib | 42.5462 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Motesanib | 48.8438 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Dasatinib | 1.1174 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Sorafenib | 35.432 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Cediranib | 7.3057 |
| SIDM00613 | LGG|glioma | p.E1069K (No) | GDSC | Foretinib | 6.7048 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Pazopanib | 9.7289 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Masitinib | 27.3898 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 5.051 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 48.1205 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | BIBF-1120 | 25.4897 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 36.1905 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Motesanib | 45.3482 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 55.615 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Dasatinib | 5.6566 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Sorafenib | 21.611 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Cediranib | 9.3666 |
| SIDM00928 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 3.5754 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Sorafenib | 9.5319 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Imatinib | 14.0616 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Pazopanib | 21.3544 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Masitinib | 24.2 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 9.9227 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 61.9427 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | BIBF-1120 | 46.2553 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 15.1592 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Motesanib | 29.9343 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 25.517 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Dasatinib | 16.928 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Sorafenib | 6.6328 |
| SIDM00879 | BRCA|breast | p.I29F (No) | GDSC | Cediranib | 7.7246 |
| SIDM00730 | SCLC|lung_small_cell_carcinoma | p.S280R (No) | GDSC | Sorafenib | 22.1058 |
| SIDM00730 | SCLC|lung_small_cell_carcinoma | p.S280R (No) | GDSC | Pazopanib | 107.739 |
| SIDM00730 | SCLC|lung_small_cell_carcinoma | p.S280R (No) | GDSC | Masitinib | 32.9006 |
| SIDM00730 | SCLC|lung_small_cell_carcinoma | p.S280R (No) | GDSC | Foretinib | 0.2468 |
| SIDM00730 | SCLC|lung_small_cell_carcinoma | p.S280R (No) | GDSC | Axitinib | 3.7743 |
| SIDM00730 | SCLC|lung_small_cell_carcinoma | p.S280R (No) | GDSC | Motesanib | 36.4324 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Masitinib | 125.5511 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Foretinib | 1.8536 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Brivanib, BMS-540215 | 104.0303 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | BIBF-1120 | 7.7033 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Axitinib | 5.4709 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Motesanib | 13.508 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Dasatinib | 0.0301 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Sorafenib | 0.5204 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Cediranib | 5.5065 |
| SIDM00969 | OV|ovary | p.T464M (No) | GDSC | Foretinib | 1.8812 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Pazopanib | 19.2114 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Masitinib | 25.8899 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 2.7102 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 73.4824 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | BIBF-1120 | 8.8868 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 11.8009 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Motesanib | 18.5066 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 10.483 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Dasatinib | 31.949 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Sorafenib | 16.964 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Cediranib | 28.435 |
| SIDM00673 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 10.663 |
| SIDM00715 | LUAD|lung_NSCLC_adenocarcinoma | p.R502W (No) | GDSC | Pazopanib | 53.4881 |
| SIDM00715 | LUAD|lung_NSCLC_adenocarcinoma | p.R502W (No) | GDSC | Masitinib | 23.6094 |
| SIDM00715 | LUAD|lung_NSCLC_adenocarcinoma | p.R502W (No) | GDSC | Foretinib | 0.7612 |
| SIDM00715 | LUAD|lung_NSCLC_adenocarcinoma | p.R502W (No) | GDSC | Brivanib, BMS-540215 | 121.4884 |
| SIDM00715 | LUAD|lung_NSCLC_adenocarcinoma | p.R502W (No) | GDSC | BIBF-1120 | 14.4091 |
| SIDM00715 | LUAD|lung_NSCLC_adenocarcinoma | p.R502W (No) | GDSC | Axitinib | 26.8735 |
| SIDM00715 | LUAD|lung_NSCLC_adenocarcinoma | p.R502W (No) | GDSC | Motesanib | 7.629 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Sunitinib | 3.6624 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Sorafenib | 1.2223 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Imatinib | 0.7577 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Dasatinib | 1.8441 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Pazopanib | 25.4173 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Masitinib | 7.6972 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Foretinib | 0.1824 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Brivanib, BMS-540215 | 30.1975 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | BIBF-1120 | 6.3128 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Axitinib | 0.5265 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Motesanib | 25.1318 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Dasatinib | 1.0506 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Sorafenib | 3.8893 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Cediranib | 1.769 |
| SIDM01245 | ALL|lymphoblastic_leukemia | p.R459H (No) | GDSC | Foretinib | 0.1768 |
| SIDM00924 | UNCLASSIFIED|lung_NSCLC_not_specified | p.P345Q (No) | GDSC | Pazopanib | 13.9355 |
| SIDM00924 | UNCLASSIFIED|lung_NSCLC_not_specified | p.P345Q (No) | GDSC | Masitinib | 113.8172 |
| SIDM00924 | UNCLASSIFIED|lung_NSCLC_not_specified | p.P345Q (No) | GDSC | Foretinib | 2.5747 |
| SIDM00924 | UNCLASSIFIED|lung_NSCLC_not_specified | p.P345Q (No) | GDSC | Brivanib, BMS-540215 | 119.7665 |
| SIDM00924 | UNCLASSIFIED|lung_NSCLC_not_specified | p.P345Q (No) | GDSC | BIBF-1120 | 96.1288 |
| SIDM00924 | UNCLASSIFIED|lung_NSCLC_not_specified | p.P345Q (No) | GDSC | Axitinib | 36.9808 |
| SIDM00924 | UNCLASSIFIED|lung_NSCLC_not_specified | p.P345Q (No) | GDSC | Motesanib | 2.9376 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Pazopanib | 36.4362 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Masitinib | 33.5782 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Foretinib | 0.9872 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Brivanib, BMS-540215 | 8.9026 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | BIBF-1120 | 60.8465 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Axitinib | 4.6289 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Motesanib | 6.6355 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Dasatinib | 2.429 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Sorafenib | 33.37 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Cediranib | 17.757 |
| SIDM00996 | THCA|thyroid | p.V221M (No) | GDSC | Foretinib | 3.8475 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Pazopanib | 117.5085 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Masitinib | 87.5893 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Foretinib | 2.6071 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Brivanib, BMS-540215 | 190.698 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | BIBF-1120 | 147.7597 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Motesanib | 18.2532 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Dasatinib | 3.6591 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Sorafenib | 14.527 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Cediranib | 11.147 |
| SIDM00753 | LUAD|lung_NSCLC_adenocarcinoma | p.L954M (No) | GDSC | Foretinib | 1.0455 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Sunitinib | 1.0259 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Sorafenib | 13.3124 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Imatinib | 11.0297 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Dasatinib | 0.0362 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Pazopanib | 7.1273 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Masitinib | 8.155 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Foretinib | 0.1714 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Brivanib, BMS-540215 | 41.0156 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | BIBF-1120 | 5.1758 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Axitinib | 2.8563 |
| SIDM00297 | LUAD|lung_NSCLC_adenocarcinoma | p.A789S (No) | GDSC | Motesanib | 3.2098 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Sunitinib | 12.0582 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Sorafenib | 3.3447 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Imatinib | 21.316 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Dasatinib | 2.8533 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Pazopanib | 45.2117 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Masitinib | 22.248 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Foretinib | 0.3964 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 189.0709 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | BIBF-1120 | 189.0709 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Axitinib | 4.9077 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Motesanib | 12.7354 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Dasatinib | 13.733 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Sorafenib | 5.8042 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Cediranib | 3.5614 |
| SIDM00257 | NB|neuroblastoma | p.I29F (No) | GDSC | Foretinib | 1.7329 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Sunitinib | 1.6083 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Sorafenib | 7.151 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Imatinib | 15.4945 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Dasatinib | 3.7375 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Pazopanib | 6.3975 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Masitinib | 1.5312 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Foretinib | 0.1774 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Brivanib, BMS-540215 | 151.9827 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | BIBF-1120 | 1.443 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Axitinib | 1.5378 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Motesanib | 10.9729 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Dasatinib | 3.3828 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Sorafenib | 5.825 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Cediranib | 4.7746 |
| SIDM00096 | UNCLASSIFIED|lymphoid_neoplasm_other | p.R502Q (No) | GDSC | Foretinib | 0.6424 |
| SIDM00534 | COREAD|large_intestine | p.A203V (No) | GDSC | Pazopanib | 34.3026 |
| SIDM00534 | COREAD|large_intestine | p.A203V (No) | GDSC | Masitinib | 21.5412 |
| SIDM00534 | COREAD|large_intestine | p.A203V (No) | GDSC | Foretinib | 4.5289 |
| SIDM00534 | COREAD|large_intestine | p.A203V (No) | GDSC | Brivanib, BMS-540215 | 95.0311 |
| SIDM00534 | COREAD|large_intestine | p.A203V (No) | GDSC | BIBF-1120 | 20.297 |
| SIDM00534 | COREAD|large_intestine | p.A203V (No) | GDSC | Axitinib | 7.3465 |
| SIDM00534 | COREAD|large_intestine | p.A203V (No) | GDSC | Motesanib | 18.0454 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Sunitinib | 336.6649 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Sorafenib | 168.3325 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Imatinib | 11.7665 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Dasatinib | 0.3358 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Pazopanib | 3.3749 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Masitinib | 265.4995 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Foretinib | 215.4655 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Brivanib, BMS-540215 | 344.8377 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | BIBF-1120 | 35.6694 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Axitinib | 84.1662 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Motesanib | 84.1662 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Dasatinib | 13.657 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Sorafenib | 120.66 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Cediranib | 138.91 |
| SIDM01175 | UNCLASSIFIED|fibrosarcoma | p.E72K (No) | GDSC | Foretinib | 6.4082 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Sunitinib | 9.6513 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Sorafenib | 8.1992 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Imatinib | 14.738 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Dasatinib | 0.4253 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Pazopanib | 18.9412 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Masitinib | 18.9999 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Foretinib | 0.9708 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Brivanib, BMS-540215 | 133.2175 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | BIBF-1120 | 8.1683 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Axitinib | 4.6398 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Motesanib | 22.5292 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Dasatinib | 0.2248 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Sorafenib | 11.044 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Cediranib | 3.243 |
| SIDM00149 | SKCM|melanoma | p.R439Q (No) | GDSC | Foretinib | 1.3132 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Pazopanib | 58.635 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Masitinib | 17.4001 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Foretinib | 0.4208 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Brivanib, BMS-540215 | 60.2221 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | BIBF-1120 | 6.9035 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Axitinib | 4.958 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Motesanib | 4.5686 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Dasatinib | 93.74 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Sorafenib | 19.111 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Cediranib | 28.594 |
| SIDM00336 | SKCM|melanoma | p.P774L (No) | GDSC | Foretinib | 18.77 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Pazopanib | 104.7675 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Masitinib | 17.593 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Foretinib | 2.0904 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Brivanib, BMS-540215 | 116.4287 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | BIBF-1120 | 39.3616 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Axitinib | 1.9595 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Motesanib | 21.8914 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Dasatinib | 0.1173 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Sorafenib | 26.115 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Cediranib | 12.854 |
| SIDM01169 | OV|ovary | p.R256W (No) | GDSC | Foretinib | 2.0914 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Sunitinib | 3.5046 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Sorafenib | 17.0004 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Imatinib | 18.6391 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Dasatinib | 11.5764 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Pazopanib | 29.8458 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Masitinib | 10.5275 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Foretinib | 0.5605 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Brivanib, BMS-540215 | 26.0028 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | BIBF-1120 | 3.0891 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Axitinib | 7.9138 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Motesanib | 12.8484 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Dasatinib | 9.2486 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Sorafenib | 5.503 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Cediranib | 5.8685 |
| SIDM00245 | SCLC|lung_small_cell_carcinoma | p.V221M (No) | GDSC | Foretinib | 3.1113 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Pazopanib | 5.4155 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Masitinib | 9.6826 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Foretinib | 0.3298 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Brivanib, BMS-540215 | 74.4383 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | BIBF-1120 | 16.3718 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Axitinib | 7.1202 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Motesanib | 15.7583 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Dasatinib | 41.705 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Sorafenib | 3.4266 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Cediranib | 5.0875 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.R459H (No) | GDSC | Foretinib | 2.1359 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Pazopanib | 5.4155 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Masitinib | 9.6826 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Foretinib | 0.3298 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 74.4383 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | BIBF-1120 | 16.3718 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Axitinib | 7.1202 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Motesanib | 15.7583 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Dasatinib | 41.705 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Sorafenib | 3.4266 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Cediranib | 5.0875 |
| SIDM01116 | UNCLASSIFIED|lung_NSCLC_large_cell | p.I29F (No) | GDSC | Foretinib | 2.1359 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Pazopanib | 22.5865 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Masitinib | 19.487 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 1.7524 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 41.363 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | BIBF-1120 | 3.6458 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 2.0552 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Motesanib | 8.301 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 1.9187 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Dasatinib | 10.556 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Sorafenib | 4.3295 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Cediranib | 6.0453 |
| SIDM00628 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 2.3916 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Pazopanib | 23.3803 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Masitinib | 99.409 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Foretinib | 5.4278 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Brivanib, BMS-540215 | 290.7788 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | BIBF-1120 | 25.7926 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Axitinib | 39.1958 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Motesanib | 13.0462 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Dasatinib | 15.233 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Sorafenib | 22.398 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Cediranib | 9.5587 |
| SIDM00545 | SKCM|melanoma | p.P1001L (No) | GDSC | Foretinib | 4.0516 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Pazopanib | 23.3803 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Masitinib | 99.409 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Foretinib | 5.4278 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Brivanib, BMS-540215 | 290.7788 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | BIBF-1120 | 25.7926 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Axitinib | 39.1958 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Motesanib | 13.0462 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Dasatinib | 15.233 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Sorafenib | 22.398 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Cediranib | 9.5587 |
| SIDM00545 | SKCM|melanoma | p.P1001S (No) | GDSC | Foretinib | 4.0516 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.S425R (No) | GDSC | Masitinib | 27.4439 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.S425R (No) | GDSC | Foretinib | 0.373 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.S425R (No) | GDSC | Brivanib, BMS-540215 | 67.0941 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.S425R (No) | GDSC | BIBF-1120 | 10.3451 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.S425R (No) | GDSC | Axitinib | 5.4599 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.S425R (No) | GDSC | Motesanib | 25.1185 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.I29F (No) | GDSC | Masitinib | 27.4439 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.I29F (No) | GDSC | Foretinib | 0.373 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 67.0941 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.I29F (No) | GDSC | BIBF-1120 | 10.3451 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.I29F (No) | GDSC | Axitinib | 5.4599 |
| SIDM00048 | LUAD|lung_NSCLC_adenocarcinoma | p.I29F (No) | GDSC | Motesanib | 25.1185 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Pazopanib | 23.2662 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Masitinib | 332.6703 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Foretinib | 121.8592 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Brivanib, BMS-540215 | 391.7555 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | BIBF-1120 | 110.2938 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Axitinib | 58.0569 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Motesanib | 58.0907 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Dasatinib | 35.375 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Sorafenib | 68.959 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Cediranib | 28.532 |
| SIDM00114 | MESO|mesothelioma | p.G1040V (No) | GDSC | Foretinib | 29.013 |
| SIDM00055 | LUAD|lung_NSCLC_adenocarcinoma | p.G1040V (No) | GDSC | Pazopanib | 10.2593 |
| SIDM00055 | LUAD|lung_NSCLC_adenocarcinoma | p.G1040V (No) | GDSC | Masitinib | 57.2385 |
| SIDM00055 | LUAD|lung_NSCLC_adenocarcinoma | p.G1040V (No) | GDSC | Foretinib | 1.4924 |
| SIDM00055 | LUAD|lung_NSCLC_adenocarcinoma | p.G1040V (No) | GDSC | Brivanib, BMS-540215 | 90.7913 |
| SIDM00055 | LUAD|lung_NSCLC_adenocarcinoma | p.G1040V (No) | GDSC | BIBF-1120 | 24.6721 |
| SIDM00055 | LUAD|lung_NSCLC_adenocarcinoma | p.G1040V (No) | GDSC | Axitinib | 14.7725 |
| SIDM00055 | LUAD|lung_NSCLC_adenocarcinoma | p.G1040V (No) | GDSC | Motesanib | 18.2117 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Sunitinib | 3.9059 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Sorafenib | 4.2358 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Imatinib | 17.0363 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Dasatinib | 4.4021 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Pazopanib | 89.53 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Masitinib | 11.6557 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Foretinib | 0.3331 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Brivanib, BMS-540215 | 5.8561 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | BIBF-1120 | 3.115 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Axitinib | 6.4852 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Motesanib | 10.2072 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Dasatinib | 2.8917 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Sorafenib | 5.5942 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Cediranib | 5.0373 |
| SIDM00289 | ALL|lymphoblastic_leukemia | p.D706N (No) | GDSC | Foretinib | 0.588 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Pazopanib | 2.7171 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Masitinib | 10.7499 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Foretinib | 0.4588 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Brivanib, BMS-540215 | 29.1383 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | BIBF-1120 | 2.1475 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Axitinib | 2.8214 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Motesanib | 7.6133 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Dasatinib | 91.699 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Sorafenib | 21.452 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Cediranib | 3.1312 |
| SIDM00548 | LUSC|lung_NSCLC_squamous_cell_carcinoma | p.E312K (No) | GDSC | Foretinib | 1.462 |
| SIDM01173 | UNCLASSIFIED|rhabdomyosarcoma | p.I29F (No) | GDSC | Sunitinib | 35.8052 |
| SIDM01173 | UNCLASSIFIED|rhabdomyosarcoma | p.I29F (No) | GDSC | Sorafenib | 4.9631 |
| SIDM01173 | UNCLASSIFIED|rhabdomyosarcoma | p.I29F (No) | GDSC | Imatinib | 5.1128 |
| SIDM01173 | UNCLASSIFIED|rhabdomyosarcoma | p.I29F (No) | GDSC | Dasatinib | 15.1594 |
| SIDM01173 | UNCLASSIFIED|rhabdomyosarcoma | p.I29F (No) | GDSC | Pazopanib | 94.7665 |
| SIDM01173 | UNCLASSIFIED|rhabdomyosarcoma | p.I29F (No) | GDSC | Masitinib | 56.0167 |
| SIDM01173 | UNCLASSIFIED|rhabdomyosarcoma | p.I29F (No) | GDSC | Foretinib | 1.7401 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Sunitinib | 9.3271 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Sorafenib | 4.0137 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Imatinib | 12.4858 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Dasatinib | 3.8375 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Pazopanib | 30.9529 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Masitinib | 11.004 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Foretinib | 0.9474 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | Brivanib, BMS-540215 | 17.8717 |
| SIDM00895 | DLBC|B_cell_lymphoma | p.R459H (No) | GDSC | BIBF-1120 | 73.2305 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Pazopanib | 11.1303 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Masitinib | 40.1793 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Foretinib | 5.8691 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Brivanib, BMS-540215 | 132.4937 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | BIBF-1120 | 108.1655 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Axitinib | 7.3026 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Motesanib | 2.1966 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Dasatinib | 25.741 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Sorafenib | 7.1731 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Cediranib | 7.764 |
| SIDM00702 | LUAD|lung_NSCLC_adenocarcinoma | p.N877T (No) | GDSC | Foretinib | 1.0477 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Sunitinib | 13.6545 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Sorafenib | 9.951 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Imatinib | 16.7523 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Dasatinib | 0.4899 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Pazopanib | 18.0763 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Masitinib | 12.1861 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Foretinib | 1.1577 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Brivanib, BMS-540215 | 227.8385 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | BIBF-1120 | 7.4024 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Axitinib | 7.9993 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Motesanib | 3.7253 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Dasatinib | 0.6167 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Sorafenib | 8.2133 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Cediranib | 2.8393 |
| SIDM00561 | UNCLASSIFIED|hairy_cell_leukaemia | p.R695C (No) | GDSC | Foretinib | 5.1757 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Sunitinib | 6.8189 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Sorafenib | 13.2872 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Imatinib | 14.8676 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Dasatinib | 12.5858 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Pazopanib | 25.2081 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Masitinib | 18.0147 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Foretinib | 0.9277 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Brivanib, BMS-540215 | 27.9965 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | BIBF-1120 | 11.7742 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Axitinib | 15.1947 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Motesanib | 31.2381 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Dasatinib | 11.657 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Sorafenib | 11.251 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Cediranib | 53.913 |
| SIDM00671 | UNCLASSIFIED|T_cell_leukemia | p.V311I (No) | GDSC | Foretinib | 21.435 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Masitinib | 10.2476 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Foretinib | 0.4288 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 11.8476 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | BIBF-1120 | 2.2437 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Motesanib | 5.7432 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Dasatinib | 14.59 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Sorafenib | 4.9872 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Cediranib | 3.3755 |
| SIDM00285 | NB|neuroblastoma | p.I29F (No) | GDSC | Foretinib | 1.2764 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Pazopanib | 21.41 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Masitinib | 16.7369 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Foretinib | 0.2996 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 39.1049 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | BIBF-1120 | 5.2417 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Axitinib | 2.1517 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Motesanib | 13.6687 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Dasatinib | 32.601 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Sorafenib | 12.33 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Cediranib | 23.146 |
| SIDM00654 | SCLC|lung_small_cell_carcinoma | p.I29F (No) | GDSC | Foretinib | 0.9613 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Pazopanib | 19.6129 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Masitinib | 99.0645 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Foretinib | 2.1363 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Brivanib, BMS-540215 | 70.4625 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | BIBF-1120 | 57.2657 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Axitinib | 47.5102 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Motesanib | 21.4873 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Dasatinib | 36.682 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Sorafenib | 10.611 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Cediranib | 18.416 |
| SIDM01124 | LUAD|lung_NSCLC_adenocarcinoma | p.P753T (No) | GDSC | Foretinib | 4.1788 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Sunitinib | 4.4835 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Sorafenib | 3.6029 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Imatinib | 24.9813 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Dasatinib | 0.0271 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Pazopanib | 18.1691 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Masitinib | 22.711 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Foretinib | 0.6635 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Brivanib, BMS-540215 | 29.5158 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | BIBF-1120 | 6.4231 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Axitinib | 6.608 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Motesanib | 17.2631 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Dasatinib | 0.5994 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Sorafenib | 17.918 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Cediranib | 13.77 |
| SIDM00133 | LUAD|lung_NSCLC_adenocarcinoma | p.E1051Q (Yes) | GDSC | Foretinib | 16.256 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Sunitinib | 5.1347 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Sorafenib | 2.7145 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Imatinib | 12.6004 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Dasatinib | 0.3089 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Pazopanib | 1.3082 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Masitinib | 15.2734 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Foretinib | 0.1134 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 29.8522 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | BIBF-1120 | 16.59 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Axitinib | 0.442 |
| SIDM00694 | UNCLASSIFIED|digestive_system_other | p.I29F (No) | GDSC | Motesanib | 12.6928 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sunitinib | 13.7971 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sorafenib | 4.2513 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Imatinib | 16.6445 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Dasatinib | 0.6238 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Pazopanib | 66.6885 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Masitinib | 22.0768 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Foretinib | 1.5241 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 22.5299 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | BIBF-1120 | 18.2753 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Axitinib | 8.4447 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Motesanib | 15.3958 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Dasatinib | 0.7575 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Sorafenib | 2.7164 |
| SIDM00808 | UNCLASSIFIED|Burkitt_lymphoma | p.I29F (No) | GDSC | Cediranib | 3.5665 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Sunitinib | 67.5213 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Sorafenib | 73.9548 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Imatinib | 26.4266 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Dasatinib | 12.3009 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Pazopanib | 187.9013 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Masitinib | 60.253 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Foretinib | 1.9663 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Brivanib, BMS-540215 | 91.5106 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | BIBF-1120 | 28.9637 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Axitinib | 37.3897 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Motesanib | 15.5156 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Dasatinib | 87.068 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Sorafenib | 14.353 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Cediranib | 50.947 |
| SIDM00653 | SCLC|lung_small_cell_carcinoma | p.A1096V (No) | GDSC | Foretinib | 9.8277 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Pazopanib | 46.4682 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Masitinib | 19.2093 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Foretinib | 1.8128 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Brivanib, BMS-540215 | 26.7771 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | BIBF-1120 | 5.9943 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Axitinib | 7.7058 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Motesanib | 9.6984 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Axitinib | 42.701 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Dasatinib | 0.3049 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Sorafenib | 15.065 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Cediranib | 3.0666 |
| SIDM00875 | UNCLASSIFIED|breast | p.A916V (No) | GDSC | Foretinib | 3.0854 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Sunitinib | 2.0978 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Sorafenib | 5.1331 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Imatinib | 7.5519 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Dasatinib | 5.9065 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Pazopanib | 14.6353 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Masitinib | 15.3116 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Foretinib | 0.9202 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | Brivanib, BMS-540215 | 43.7305 |
| SIDM00390 | UNCLASSIFIED|anaplastic_large_cell_lymphoma | p.R502W (No) | GDSC | BIBF-1120 | 2.3434 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Pazopanib | 10.6188 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Masitinib | 24.3382 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Foretinib | 1.7554 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Brivanib, BMS-540215 | 91.239 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | BIBF-1120 | 9.2764 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 5.1929 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Motesanib | 42.2561 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Axitinib | 5.9391 |
| SIDM00878 | BRCA|breast | p.I29F (No) | GDSC | Sorafenib | 10.531 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Pazopanib | 34.8231 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Masitinib | 50.7859 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Foretinib | 0.7394 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Brivanib, BMS-540215 | 240.5601 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | BIBF-1120 | 46.4526 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Axitinib | 30.9296 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Motesanib | 8.1859 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Dasatinib | 20.465 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Sorafenib | 286.31 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Cediranib | 12.444 |
| SIDM00571 | UNCLASSIFIED|pancreas | p.R685C (No) | GDSC | Foretinib | 50.357 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Sunitinib | 52.1035 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Imatinib | 8.9286 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Dasatinib | 3.8535 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Pazopanib | 6.9146 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Masitinib | 28.5495 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Foretinib | 2.1468 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Brivanib, BMS-540215 | 38.9131 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | BIBF-1120 | 9.5054 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Axitinib | 9.0096 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Motesanib | 13.5253 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Dasatinib | 0.5826 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Sorafenib | 1.8403 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Cediranib | 3.3638 |
| SIDM00424 | UNCLASSIFIED|B_cell_leukemia | p.R273H (No) | GDSC | Foretinib | 1.6616 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Sorafenib | 2.2419 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Pazopanib | 102.78 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Masitinib | 51.1198 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Foretinib | 3.6532 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Brivanib, BMS-540215 | 110.6657 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | BIBF-1120 | 53.3315 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Axitinib | 18.812 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Motesanib | 6.3211 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Dasatinib | 31.269 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Sorafenib | 7.5049 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Cediranib | 5.8015 |
| SIDM00118 | COREAD|large_intestine | p.E253* (No) | GDSC | Foretinib | 4.088 |
| SIDM00608 | MM|myeloma | p.V84M (No) | GDSC | Masitinib | 22.102 |
| SIDM00608 | MM|myeloma | p.V84M (No) | GDSC | Foretinib | 0.3571 |
| SIDM00608 | MM|myeloma | p.V84M (No) | GDSC | Brivanib, BMS-540215 | 37.787 |
| SIDM00608 | MM|myeloma | p.V84M (No) | GDSC | BIBF-1120 | 32.9443 |
| SIDM00608 | MM|myeloma | p.V84M (No) | GDSC | Axitinib | 7.9046 |
| SIDM00608 | MM|myeloma | p.V84M (No) | GDSC | Motesanib | 7.8351 |
All proteins holding degron of VNTSS
| Uniprot ID | Source protein | Degron class | Location | Hit | E3 ligase | Degron score | Detail |
| P09619 | Platelet-derived growth factor receptor beta | DEG_SPOP_SBC_1 | 1052:1056 | VNTSS | SPOP | 0.9079 | More... |
| Q8IZP9 | Adhesion G-protein coupled receptor G2 | DEG_SPOP_SBC_1 | 369:373 | VNTSS | SPOP | 0.9386 | More... |
| Q8TAX7 | Mucin-7 | DEG_SPOP_SBC_1 | 145:149 | VNTSS | SPOP | 0.9158 | More... |
| Q8WWK9 | Cytoskeleton-associated protein 2 | DEG_SPOP_SBC_1 | 221:225 | VNTSS | SPOP | 0.9787 | More... |
| Q9H6R7 | WD repeat and coiled-coil-containing protein | DEG_SPOP_SBC_1 | 482:486 | VNTSS | SPOP | 0.7588 | More... |
| O94913 | Pre-mRNA cleavage complex 2 protein Pcf11 | DEG_SPOP_SBC_1 | 154:158 | VNTSS | SPOP | 0.9935 | More... |
| Q96KR1 | Zinc finger RNA-binding protein | DEG_SPOP_SBC_1 | 456:460 | VNTSS | SPOP | 0.7805 | More... |
| Q6Q759 | Sperm-associated antigen 17 | DEG_SPOP_SBC_1 | 11:15 | VNTSS | SPOP | 0.8744 | More... |